Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept* IL-1α & IL-1β Recurrent Pericarditis End Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab** GM-CSFRα Giant Cell Arteritis Phase 2
COVID-19 Pneumonia & Hyperinflammation Phase 2
Vixarelimab*** OSMRβ Prurigo Nodularis Phase 2
KPL-404 CD40 T-Cell Dependent, B-Cell–Mediated Indications Phase 1
*The FDA accepted the sBLA with priority review and assigned a PDUFA goal date of March 21, 2021; The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept for pericarditis in 2020.
** The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020.
***The FDA granted Breakthrough Therapy designation to vixarelimab for pruritus associated with prurigo nodularis in 2020.

Every Second Counts!